Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Citi analysts have advised investors to sell shares of Moderna, arguing that the company's revenue and profit projections do not support the large increase already priced into its stock. The recommendation follows a more than 600% rise in Moderna's share price.
Why It Matters
An analyst downgrade from a major bank on valuation grounds can influence investor sentiment and trading flow, especially after substantial prior gains. If Citi's view is echoed by other institutions, it could prompt reassessment of vaccine- and biotech-related valuations.
Key Facts
- Analyst: Citi analysts
- Recommendation: Sell
- Company: Moderna
- Reason cited: Revenue and profit forecasts do not justify current share price
- Share-price move referenced: More than 600% gain
Citi's research team has told clients it is time to sell Moderna stock, saying the company's forward revenue and earnings projections fall short of supporting the valuation now reflected in its share price. The call highlights a gap between the market's enthusiasm for Moderna and the financial outlook Citi expects the company to deliver.
The bank's note points directly to Moderna's recent run-up in market value, noting the stock has climbed by over 600% from prior levels. Citi's analysts argue that this surge appears to have baked in expectations that future sales and profits will be substantially higher than the firm's forecasts allow.
While the analyst note focuses on valuation and forecasted financials, it does not, in the material provided, detail specific numeric targets or a timetable for their outlook. The downgrade from a major financial institution arrives at a moment when investor attention on vaccine developers and biotech names remains elevated following pandemic-era performance.
Market participants often react to such high-profile analyst calls, and similar assessments from other brokerages could prompt further reassessments of Moderna's valuation. Citi's view underscores the tension between strong historical price appreciation and the need for matching fundamentals to justify those gains.
Keep Reading
Agencies publish resolution plan feedback letters for 15 banking organizations
Federal Reserve Board finalizes changes to enhance the transparency and public accountability of its stress test and reduce volatility in its stress test-related capital requirements
A tough job market is pushing more young Americans to make a big bet: on themselves
